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Abstract
Background and aims: Cervicogenic headache (CEH) is a 
debilitating condition and analgesics have limited effect. 
Percutaneous cryoneurolysis is thus still in use although 
the clinical evidence is lacking. We present a randomized, 
controlled study to assess the clinical efficacy of cryoneu-
rolysis compared with a corticosteroid combined with a 
local anaesthetic.
Methods: In a university-based outpatient pain clinic we 
performed a randomized, double blinded, comparative 
study with an 18-week follow-up. After positive diagnostic 
test blocks 52 eligible patients were randomly allocated in 
a ratio of 3:2, 31 participants to occipital cryoneurolysis 
and 21 participants to injections of 1 mL methylpredniso-
lone 40 mg/mL (Depo-Medrol®) combined with 1 mL bupi-
vacaine 5 mg/mL.
Results: We observed a significant pain reduction of more 
than 50% in both treatment groups, slightly improved neck 
function and reduced number of opioid consumers. After 
6–7-weeks, however, pain intensity increased gradually, 
but did not reach baseline within 18 weeks. Although cry-
oneurolysis provided a more prolonged effect, the group 
differences did not reach statistical significance. Health 
related quality of life and psychological distress improved 
minimally. A large number reported minor and transient 
side effects, but we found no significant group differences. 
After 18 weeks, 29% rated the headache as much improved, 
and 12 (24%) somewhat improved, but a large proportion 
(78%) reported need for further intervention/treatment.
Conclusions: Cryoneurolysis provided substantial, but 
temporary pain relief, and the effect was not significantly 
different from injections of a corticosteroid combined with 
a local anaesthetic. Participants were selected by a single 
test block, and the neurolytic procedure was guided by ana-
tomical landmarks and nerve stimulation. A stricter patient 
selection and an ultrasound-guided technique might have 
improved the results. Cryoneurolysis provides temporary 
pain relief not significantly superior to corticosteroid injec-
tion, and the results question the value of occipital cry-
oneurolysis for a chronic pain condition like CEH.
Implications: Occipital cryoneurolysis may be considered 
when non-invasive treatments appear insufficient, but 
only for patients who have responded substantially to 
test blocks. A risk of local scar and neuroma formation by 
repeated cryoneurolysis, leading to neuropathic pain has 
been discussed by other researchers.
Keywords: cryoneurolysis; cryoablation; cryoanalgesia; 
treatment; occipital; cervicogenic headache.
1   Introduction
Cervicogenic headache (CEH) is a debilitating condition 
and is frequently associated with long term sick leave 
[1]. The prevalence rates in previous European studies 
vary from 15 to 18% [2, 3], and in patients with a defined 
 whiplash-associated disorder Australian researchers 
diagnosed CEH in 53% of the patients [4]. In contrast to 
these rates, two small Norwegian population studies have 
presented prevalence rates of 0.17% and 4.1%, respec-
tively [5, 6].
CEH is a controversial diagnosis [7], but is catego-
rised as a secondary headache (ICHD-II 2004) related to 
injury, inflammation or degenerative changes in the cervi-
cal spine [8, 9]. It is typically characterized by unilateral 
headache, with frequent attacks of moderate to severe 
intensity spreading from the neck up to occiput and some-
times even to the frontotemporal area [10]. The patients 
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may report blurred vision, dizziness, and hypersensitiv-
ity to light and sound and the symptoms may thus mimic 
migraine. However, it has rarely the throbbing and pulsat-
ing character [8–11].
Analgesics have limited effect [12], and there is no 
standard algorithm on how to treat refractory cases of CEH 
[13]. As the index area of pain is innervated by well-defined 
branches of the nerve roots C2 and C3, like the greater occip-
ital nerve (GON), lesser occipital nerves (LONs) including 
the greater auricular nerve (GAN), local anaesthetic nerve 
blocks have been used clinically to diagnose CEH [14].
Some pain centres apply occipital cryoneurolysis 
to prolong the analgesic effect [15–17]. This represents a 
nerve destructive technique where freezing is applied 
to block nerve conduction. Freezing the nerve leads to 
crystal formation with rupture of cell membranes, protein 
denaturation, and cellular dehydration [16], but oblitera-
tion and damage to the vasa nervorum and autoimmune 
responses have also been suggested as potential mecha-
nisms [15, 18, 19]. The endoneurium and basal lamina of 
the Schwann cells, however, remain intact and the nerve 
has therefore a potential to regenerate [20–22].
The evidence on cryoneurolysis is mostly based on 
non-randomized studies or case series [17, 23]. So far, 
there is only one randomized, controlled trial available 
on patients with knee osteoarthritis [24] and none support 
occipital cryoneurolysis for CEH. To improve the clinical 
evidence on long-term effect for patients with CEH, we per-
formed a randomized, controlled study which compared 
occipital cryoneurolysis with injections of a corticosteroid 
combined with a local anaesthetic. Our hypothesis was 
that occipital cryoneurolysis provides longer pain reduc-
tion than a corticosteroid injection.
2   Materials and methods
2.1   Design
The study had a prospective, randomized, double blinded, 
comparative design with an 18-week follow-up. Patients 
were randomly allocated in a ratio of 3:2 to either occipital 
cryoneurolysis or injections of a corticosteroid combined 
with a local anaesthetic.
2.2   Setting
The study was carried out at a University-Hospital Pain 
Clinic, approved by The Regional committee for Medical 
and Health Research Ethics (10.09.2002, reference number 
344-02150), and did not receive any external funding.
2.3   Recruitment and selection
We recruited CEH patients by advertising in a local 
newspaper. Inclusion criteria included unilateral CEH, 
diagnosed according to the Sjaastad criteria [14], with a 
maximum headache intensity of ≥40 (0–100  scale), not 
responding to conservative treatment, and with an age 
between 18 and 65  years. Exclusion criteria included 
bleeding diathesis, allergy to a local anaesthetic agent, 
local skin infection, progressive or serious cardiovascu-
lar disease, diabetes mellitus, pregnancy, cognitive defi-
ciency, previous cryoneurolysis or occipital injection with 
a local anaesthetic agent last 4 weeks (8 weeks if corticos-
teroid), and language barriers.
A total of 172 persons responded to the advertisement 
between October 2002 and April 2003, and of these 86 indi-
viduals were screened with a self-report questionnaire. 
Sixty-seven persons were invited for further examination 
by an experienced physiotherapist (SMA) and subjected to 
diagnostic test blocks carried out by an experienced inter-
ventionist (HH).
2.4   Diagnostic nerve blocks
The diagnostic blocks of the GON and LONs and in some 
cases the GAN were conducted under aseptic conditions 
after infiltration of lidocaine 10  mg/mL with adrenaline 
5  μg/mL into the subcutaneous tissue. The insertion 
of a 14  G introducer needle was guided by anatomical 
(muscular and bony) landmarks [25] and high-frequency 
stimulation (100  Hz) with the SL 2000 Lloyd Neurostat 
Cryosurgical System (Integra Neurosciences, previous 
Spembly Medical, Newbury Road, Andover, Hampshire, 
SP10 4DR, England) including an 18 G cryoprobe (Lloyd 
cryosurgical probe, Series 44 44-1H3 S/N Art code 
146800M2). Stimulus duration remained at 10  ms while 
the voltage decreased from two volts down to a level 
between 0.5 and 0.2 V. To obtain an optimal position close 
to the target nerve, paraesthesia should still be perceived 
in the area of maximal pain before 1.5–2 mL of bupivacaine 
5 mg/mL was injected.
Pain intensity and side effects were registered 30 min, 
2 h and 24 h after the test block. Those who satisfied inclu-
sion criteria (listed above) and reported a clinically sig-
nificant response (preferably >50% pain reduction) after 
30  min and 2  h, were found eligible for inclusion. They 
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received detailed information including potential side 
effects and complications before informed consent was 
obtained.
2.5   Randomisation and blinding
The participants were randomly allocated by computer-
generated sequence generation carried out by one of the 
researchers (JHR), not involved in the intervention. The 
allocation was kept concealed in an envelope until the 
day of intervention. As participants were lying in a prone 
position with extensive covering, and the skin infiltrated 
by a local anaesthetic agent, they were not able to observe 
nor register what kind of treatment that was given. Partici-
pants and assessor (SMA), the latter not present at treat-
ment, were kept blinded throughout the follow-up.
2.6   The cryoneurolysis procedure
The intervention was performed percutaneously. Under 
aseptic conditions cutaneous and subcutaneous tissue 
was infiltrated with lidocaine 10 mg/mL with adrenaline 
5  μg/mL. The needle insertion (14 G introducer needle) 
was guided by anatomical (muscular and bony) land-
marks [25] and high-frequency nerve stimulation (100 Hz), 
as described for the diagnostic test block.
The cryoneurolysis was performed by the SL 2000 
Lloyd Neurostat Cryosurgical System and the 18 G cryo-
probe inserted through the introducer needle. The 
cryoprobe is an adaptation of Amoils’ gas-expansion pro-
totype and with 8–10 L/min N2O gas, circulating within a 
closed tubal system of the cryoprobes, the tip tempera-
ture drops rapidly down to −60 °C (Adiabatic principle/
Joule- Thompson effect). This low temperature is neces-
sary to freeze, disrupt the cell membrane, and induce cell 
death [15]. Each freezing session lasted for 90 s and was 
repeated 2–3 times with intervals of 1.5–3 min to increase 
the lesion size (ice-ball) [16, 26]. To avoid nerve avulsion, 
we defrosted the probe for 30 s before it was withdrawn.
2.7   The control procedure
The intervention was similarly performed under aseptic 
conditions. After infiltration with lidocaine 10  mg/mL 
with adrenaline 5 μg/mL into the subcutaneous tissue 
the needle insertion was guided by anatomical (mus-
cular and bony) landmarks [25] and nerve stimulation 
(as described for the diagnostic test block). Then 1  mL 
methylprednisolone 40 mg/mL (Depo-Medrol®) combined 
with 1 mL bupivacaine 5 mg/mL was injected.
2.8   Data collection
The outcome measures follow the IMMPACT recommen-
dations [27]. Primary outcome was “worst pain intensity” 
quantified by a 0–100  scale and based on daily records 
during the first 6 weeks transformed to weekly replicates, 
and weekly records from week 7–18.
Secondary outcomes included numbers of success-
ful treatment (30% and 50% pain reduction), proce-
dural pain, side effects and complications, and changes 
in psychological distress, health related quality of life, 
self-reported change in neck function and range of active 
cervical movement (ROM) like flexion, extension, left 
and right lateral flexion, right and left rotation, and the 
patients’ global impression of change, specific impression 
of change of pain (headache), consumption of analgesics, 
occupational status, how they experienced the treatment, 
need for further treatment, desire for a repeated interven-
tion or another treatment.
Before treatment the participant filled in a question-
naire including demographics (gender, age, height and 
weight and occupational status) and clinical information 
about comorbidity and headache (onset and duration, 
temporal pain profile, location, worst and least pain inten-
sity during the last week and last month), other symptoms 
like sensitivity to light and sound, blurred vision, dizzi-
ness, lack of concentration and memory, psychological 
distress by Hopkins Symptom Check List 25 (HSCL 25) 
and Health-related Quality of Life by RAND 36 (Version 1) 
including eight domains such as vitality, physical func-
tioning, bodily pain, general health perceptions, physical 
role functioning, emotional role functioning, social role 
functioning, and mental health. A physical examination 
assessed active range of cervical ROM with a goniometer 
and counted number of palpable trigger points in the neck 
and occipital region.
After treatment the participants recorded worst and 
least pain intensity on a 0–100 scale in a diary, daily during 
the first 6 weeks and weekly during the next 12 weeks. At 
the 1, 6 and 18-week follow-ups they were asked to report 
on side effects or complications, their own experience of 
neck movement, their impression of change in neck move-
ment (5-point scale, with 1 = much better, 5 = much worse), 
health-related quality of life and psychological distress, 
migraine, and consumption of analgesics. An independ-
ent and blinded assessor (SMA) investigated active cervical 
ROM. In cases of missing values, the subjects were politely 
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asked to give an answer. At the final meeting (week 18) 
they were also asked to report on their global impression 
of change (5-point scale; 1 = much better, 5 = much worse), 
their impression of change of the headache (5-point scale, 
1 = much worse, 5 = much better), occupational status, 
how they experienced the treatment, whether they were 
in need of further treatment, wanted another treatment 
or to repeat the intervention, their experience of the inter-
vention (rated by a 4-point scale; 1 = very uncomfortable 
and 4 = not uncomfortable at all), and rated the result of 
the intervention compared to previous treatments at the 
pain clinic (graded by a 3-point scale; 1 = worse, 2 = same, 
3 = better).
2.9   Statistics
For the statistical analyses we used the SPSS statistical 
package, version 25 and Excel (Microsoft Office 2016). To 
compare categorical variables between two groups, we 
used the Chi Square (χ2) test or Fisher exact test when any 
of the cells had expected values less than 5. To perform 
paired categorical comparisons, we used NcNemar test.
Baseline comparisons for continuous variables were 
carried out by General Linear Model Repeated Measures 
as the residuals were found normally distributed on the 
Q-Q plot. A subanalysis was performed of those who 
obtained >50% pain reduction to the test block, to assess 
the success rates of the two treatments (i.e. numbers who 
reached 30% or 50% pain reduction after treatment). 
Group comparisons with continuous variables were 
carried out by the GLM Univariate ANCOVA to adjust for 
different baseline levels or by the Independent sample 
Student t-test as the data were found normally distrib-
uted on the Q-Q plot. The data analysis of the secondary 
outcome variables presented is considered exploratory. 
Consequently, multiple tests were done without multiplic-
ity correction [28]. The selected sample size of the study 
is supported by previous and more recent randomized, 
controlled intervention studies of the occipital nerves and 
medial branches [29–32].
3   Results
A total of 52 patients were included in the study, 27 (52%) 
were males and 25 (48%) females. Those subjected to cry-
oneurolysis were younger (p = 0.001) with mean age of 
45.8 (10.5) years vs. 55.8 (8.3) years in the injection group. 
Thirty-one participants received cryoneurolysis while 21 
injections on the occipital nerves with a corticosteroid 
in combination with a local anaesthetic. One participant 
in the injection group dropped out at the last follow-up 
(Fig. 1).
3.1   Headache characteristics
Average duration of the headache was 13 (SD 10) years. 
Half of the participants (n: 26) reported a history of whip-
lash and 10 participants another injury to the head or 
neck. About one fourth (n: 12) had no history of injury. A 
high proportion (42%) reported concomitant migraine.
All participants suffered from unilateral occipital 
headache, and for the large majority (80–90%) the pain 
radiated to the frontal, temporal, or orbital areas of the 
head (Table 1). At inclusion the participants reported high 
pain intensity scores during the last week [mean 63 (SD 
23) in the injection group and 68 (SD 20) in the cryoneu-
rolysis group], and a clinically significant response to the 
test block, for 70% of the sample more than 50% pain 
reduction after 30 min and 2 h. Neither group differences 
of baseline characteristics nor responses to test blocks 
reached statistical significance (See Table 1).
3.2   Pain assessment
For the primary outcome measure, pain intensity, we 
observed substantial and statistically significant pain 
reductions in both treatment groups from pain inten-
sity scores at 63 (injection group) and 68 (cryoneurolysis 
group), respectively down to a score approximating 30, 
which is equivalent to a 50% reduction in the injection 
group and 55% after cryoneurolysis. From week 6 and 7 
after the intervention, pain increased gradually and lev-
elled off at 50 in the injection group and 40–45 in the cry-
oneurolysis group and did not reached baseline within 
18 weeks (Fig. 2).
Group comparisons at 1, 6, and 18 weeks (Table 2) and 
the average levels of week 1–6 and week 7–18 showed no 
significant differences. For weekly group comparisons, 
adjusted for different baseline pain levels (Univariat 
ANCOVA), the cryoneurolysis group reported statistically 
significantly lower pain levels at week 7 (p = 0.02) and 
week 17 (p = 0.04) but not for the other weeks (Fig. 2). 
Neither did the proportions of successful treatments 
within each group (i.e. those who achieved 30% and 50% 
reduced pain intensity) differ significantly at the three 
follow-ups (Table 3). A subanalysis, including only the 
participants who obtained >50% pain reduction after test 
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Excluded not responding to test
block (n = 15)
Analysed (n = 20)
• Excluded from analyses (n = 1)
Lost to the last follow-up at 18 weeks (n = 1)
Allocated to occipital injection of a corticosteroid and
local anaesthetic (n = 21)
• Received allocated intervention (n=21)
Lost to follow-up (n = 0)
Allocated to occipital cryoneurolysis (n = 31)
 • Received allocated intervention (n = 31)
Analysed (n = 31)




Randomized (n = 52)
Ratio 3:2 
Excluded not meeting inclusion
criteria (n = 86)
Excluded not meeting inclusion
criteria (n = 19)
Allocation
Clinical screening examination
with diagnostic test blocks (n: 67)
Responders to public
announcement (n = 172)
Pre-screened by telephone-based
interview (n = 172)
Screened by a self-report
questionnaire (n = 86)
Fig. 1: Flow chart.
block, did not improve the numbers who reached 30% or 
50% pain reduction after treatment.
After 18  weeks 15 of the whole sample (29%) rated 
the headache as much improved, 12 (24%) somewhat 
improved while 24 (47%) as unchanged, but none 
reported worse headache. We found no significant differ-
ence between the groups (group-specific data are shown 
in Table 4). Even so, large proportions reported need for 
further intervention (70% in the injection group vs. 83% in 
the cryoneurolysis group) and desire to another treatment 
(70% in the injection group vs. 77% in the cryoneurolysis 
group).
3.3   Procedural pain
Thirty minutes after the cryoneurolysis pain intensity 
averaged 30, and 9 (29%) participants reported a pain 
level >40. Average pain intensity after corticosteroid injec-
tions was significantly lower at 15 (p = 0.02) and only three 
participants (15%) reported a pain level >40. Among those 
who underwent cryoneurolysis, 11 (35%) participants 
needed intravenous dosages of an opioid (alfentanil) vs. 
only two (10%) in the injection group. At the end of the 
study (18  weeks), 37% rated cryoneurolysis as moder-
ately to very uncomfortable vs. 24% in the corticosteroid 













 Age (years) 49.8 (10.8) 55.8 (8.3) 45.8 (10.5) 0.001
 Headache duration (years) 15 (10) 18 (11) 13 (9) 0.08
n (%) n (%) n (%)
 Males 27 (52%) 11 (52%) 16 (52%) 0.96
 Females 25 (46%) 10 (48%) 15 (48%)
Occupational status
 Full time work 16 (32%) 5 (24%) 11(38%) 0.64
 Part time work 2 (4%) 1 (5%) 1 (3%)
 Receiving social benefits 28 (56%) 13 (62%) 15 (52%)
 Receiving age pension 4 (8%) 2 (10%) 2 (7%)
Pain attribution
 Wiplash injury 26 (50%) 11 (52%) 15 (48%) 0.26
 Other head or neck injury 10 (19%) 6 (29%) 6 (19%) 0.72
 No injury 12 (23%) 5 (24%) 7 (23%) 1.0
Pain location
 Right side (n: 51) 29 (57%) 11 (52%) 18 (60%) 0.59
 Left side (n: 51) 22 (43%) 10 (48%) 12 (40%) 0.59
 Pain radiating to:
  Vertex (n: 51) 31 (61%) 9 (45%) 22 (71%) 0.09
  Orbital area 46 (88) 18 (86%) 28 (90%) 0.61
  Temporal area 43 (83%) 15 (71%) 28 (90%) 0.08
  Frontal area 41 (79%) 18 (86%) 23 (74%) 0.32
  The jaw 25 (48%) 12 (57%) 13 (42%) 0.28
  Temporomandibular and ear region 28 (54%) 14 (67%) 14 (42%) 0.13
  Shoulder 41 (79%) 15 (71%) 26 (84%) 0.28
  Arm 32 (62%) 12 (57%) 20 (65%) 0.59
Number of analgesic consumers
 Participants taking analgesics regularly 22 (42%) 10 (48%) 12 (39%) 0.89
 Participants taking analgesics when needed 37 (71%) 18 (86%) 19 (61%) 0.28
 Participants taking opioid 27 (52%) 13 (62%) 14 (45%) 0.24
Previous treatments
 Injections with LA and corticosteroid 25 (48%) 10 (48%) 15 (48%) 0.96
 Radiofrequency 7 (13%) 1 (5%) 6 (19%) 0.13
 Physiotherapy 42 (81%) 17 (81%) 25 (81%) 0.98
 Manual therapy 34 (65%) 14 (67%) 20 (65%) 0.87
 Acupuncture 35 (67%) 17 (81%) 18 (58%) 0.08
 TENS/Electroacupuncture 16 (31%) 8 (38%) 8 (26%) 0.35
 Other treatments 13 (25%) 4 (19%) 9 (29%) 0.42
Cervical range of movement
 Flexion 41.80 (13.00) 39.90 (11.60) 43.10 (13.80) 0.4
 Extension 45.00 (17.20) 45.30 (13.40) 44.70 (19.60) 0.9
 Right rotation 48.60 (13.40) 48.30 (14.70) 48.80 (12.70) 0.9
 Left rotation 47.90 (13.10) 48.90 (13.50) 47.30 (12.90) 0.7
 Lateral right flexion 31.50 (12.00) 31.10 (13.70) 31.70 (11.00) 0.9
 Lateral left flexion 31.30 (10.20) 29.80 (9.90) 32.40 (10.30) 0.4
HSCL 25 sum score 1.8 (0.5) 1.7 (0.4) 1.9 (0.6) 0.2
Health-related quality of life (RAND 36)
 Mental health 68.85 (18.50) 72.38 (14.14) 66.45 (20.83) 0.23
 Vitality 37.58 (19.46) 43.67 (16.79) 33.66 (20.30) 0.07
 Bodily pain 31.81 (21.37) 36.86 (25.10) 28.39 (18.08) 0.16
 General health 56.02 (20.62) 55.89 (21.02) 56.10 (20.74) 0.97
 Sosial function 63.52 (26.06) 66.88 (25.09) 61.21 (26.37) 0.41
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injection group. However, despite these numbers 46 out 
of 50 (92%) wanted repeated treatment, and we found no 
difference between the groups.
3.4   Neck function
Baseline range of movement (ROM) of the whole sample 
was moderately limited (70–75%) compared with normal 
data on people between 35 and 45  years [33, 34] and 
improved slightly at the follow-ups, and statistically sig-
nificant only for right rotation (p < 0.001).
At the three follow ups 32%, 29%, and 29% reported 
an impression of improved neck movement after cryoneu-
rolysis vs. 52%, 39%, 28% after corticosteroid injections 
(Table 4). The participants who experienced worse neck 
movement after cryoneurolysis, declined from 10% to 6%. 
No one reported worse neck movement after corticoster-
oid injections. We found no significant group difference.
3.5   Occupational status
At baseline a total of 16 participants (35%) worked full time 











 Physical function 75.82 (22.84) 74.30 (23.21) 76.85 (22.91) 0.70
 Role-physical 30.21 (38.23) 28.95 (41.89) 31.03 (36.39) 0.86
 Role-emotional 54.86 (44.29) 61.11 (44.65) 51.11 (44.41) 0.46
Group comparisons of the categorical variables were performed by the χ2 test and Independent Sample Student t-test for continuous data. 
No post hoc tests were performed. aSignificant group differences with p < 0.05. Cryo = cryoneurolysis; S + LA = corticosteroid combined with 


















* * * * * * * * * * * * * * * * * *
Fig. 2: Values are presented as means with standard deviation. 
From week 1–6 daily records of pain intensity are averaged 
and presented as weekly replicates. Statistical within-group 
comparisons were performed with GLM Repeated measurement 
(n: 46). Due to different baseline levels between-group 
comparisons (n: 51) were performed with Univariate ANCOVA 
with baseline pain intensity as covariate. Post hoc tests 
were not performed. *indicates a statistically significant 
difference from baseline (p  ≤  0.002) (within-group comparison) 
while $ indicates a statistically significant difference 
between the groups (p < 0.05). VAS = visual analogue scale; 
Cryo = cryoneurolysis; S + LA = corticosteroid combined with local 
anaesthetic injection.






















Mean  SD Mean  SD Mean  SD Mean  SD
Whole sample  66  21  35  24    <0.001a  30  22    <0.001a  45  33    <0.001a
S + LA   63  23  31  21  −18.6 to 7.9   0.42b  28  20  −13.3 to 11.4  0.88b  51  35  −7.2 to 30.2  0.22b
Cryo   68  23  38  21   31  20   41  35
The statistical within group comparisons (differences to baseline) were performed with GLM Repeated Measures, while between-group 
comparisons were performed with Univariate ANCOVA with baseline pain intensity as covariate due to different baseline levels. ap-Value is 
based on within-group comparison. bp-Value is based on between-group comparisons (n: 51). Daily records of pain intensity are averaged 
to weekly replicates and presented for week 1 and 6. Statistical significance considered when p-values < 0.05 and no post hoc tests were 
performed. SD = standard deviation; CI = 95% confidence interval; Cryo = cryoneurolysis; S + LA = corticosteroid combined with local 
anaesthetic injection.
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number in full time work had increased to 20 (43%) and 
on social benefits decreased to 23 (50%). We found no 
significant change from baseline nor between the groups. 
Participants on old age pension (n: 4) were excluded from 
the analysis.
3.6   Psychological distress
At baseline, HSCL 25 sum score averaged 1.83 (SD 0.49), 
indicating increased psychological distress for the whole 
sample, but we observed no significant change through-
out the study nor any group differences even when adjust-
ing for different baseline between the groups.
3.7   Health-related quality of life
For health-related quality of life (RAND 36) we measured 
large variations between the different domains from high 
levels on physical function and mental health, to low 
levels for bodily pain, vitality and physical role. During the 
follow-up there was minimal improvement from baseline, 
except for bodily pain at the 6-week follow up (p = 0.03), 
and a significant group difference (lowest level in the 
injection group) only for mental health at the 18-week 
follow up (p = 0.04).
3.8   Global impression of change and 
grading of the interventions
At the 18-week follow up 23 (55%) of the participants 
reported “much improved” and 8 (19%) “moderately 
improved” global status. One of the participants reported 
a worse global status. (Group specific data are shown in 
Table 4.) The participants rated the occipital interventions 
superior to previous treatments at the pain clinic, but sta-
tistical comparisons of these global measures showed no 
group difference.
3.9   Consumption of analgesics
At baseline 23 of the participants (44%) took analgesics 
when needed while 11 (21%) reported regular use. At 
the end of the study these numbers had declined to 16 
(31%) and 5 (10%), respectively. We found a correspond-
ing reduction in the number of opioid consumers from 26 
(50%) to 22 (42%), but the change from baseline nor the 
group difference did not reach statistical significance.


















Pain reduction n (%) n (%) n (%)
>30%   13 (62)  18 (62)  0.99  12 (57)  22 (76)  0.16  9 (47)  12 (46)  0.94
>50%   12 (57)  14 (48)  0.54  10 (48)  17 (59)  0.44  8 (42)  9 (35)  0.61
Group comparisons of the categorical variables were performed by the χ2 test for both 30% and 50% reduction of pain intensity. We 
considered p-values < 0.05 as statistically significant as post hoc test for multiple comparisons were not performed. Cryo = cryoneurolysis; 
S + LA = corticosteroid combined with local anaesthetic injection.
















S + LA   Cryo S + LA   Cryo S + LA   Cryo S + LA   Cryo S + LA   Cryo
n (%)
Global status   7 (44)   16 (62)   5 (31)   3 (12)   10 (24)   6 (20)   0 (0)   0 (0)   0 (0)   1 (4)
Headache intensity  5 (25)   10 (32)   5 (25)   7 (23)   10 (50)   14 (45)   0 (0)   0 (0)   0 (0)   0 (0)
Neck movement   3 (14)   4 (13)   3 (14)   5 (16)   14 (67)   20 (65)   0 (0)   1 (3)   0 (0)   1 (3)
Group comparisons of the categorical variables were performed by the χ2 test. We considered p-values < 0.05 as statistically significant 
as post hoc test for multiple comparisons were not performed. There were no statistically significant differences between the groups. 
Cryo = cryoneurolysis; S + LA = corticosteroid combined with local anaesthetic injection.
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3.10   Side effects and complications
We received several reports of transient and minor side 
effects such as local pain/tenderness, dizziness, and seda-
tion; the day after intervention by 15 participants (29%), 
and at the three follow-ups by 9 (17%), 4 (8%) and 1 (2%), 
respectively, but the group differences did not reach statis-
tical significance. One participant became acutely ill imme-
diately after a small injection (3 mL) of methylprednisolone 
and bupivacaine close to the minor occipital nerve. She 
developed transient disturbed consciousness, visual prob-
lems, unilateral motor deficiency, and chest pain and was 
immediately transferred to the intensive care unit. Cardiac 
and neurological examination, however, could not give any 
explanation, and she recovered within a few hours without 
any sequelae and was willing to complete the study.
4   Discussion
4.1   Main findings
This is the first published randomized, controlled trial on 
CEH comparing occipital cryoneurolysis with injections 
of corticosteroid combined with a local anaesthetic. Our 
main finding is that both corticosteroid injections and 
cryoneurolysis provide clinically significant pain reduc-
tion (50% and 60%, respectively). After 6 and 7  weeks, 
the effect gradually subsided and pain intensity reached 
a level 85% and 60% of baseline, respectively. We also 
observed a trend towards a lower number of opioid con-
sumers. At the 18-week follow up a large majority (74%) 
of the participants reported much or moderately improved 
global status while approximately half of the participants 
reported less pain/headache (57%) or improved neck 
movement (57%) (Table 4). This may reflect that global 
status is also influenced by other factors than the analgetic 
effect. The effect of increased attention as a study partici-
pant (Hawthorne effect) has been shown to have a strong 
influence on study outcomes [35]. To sum up, there was no 
overall significant difference between the two treatment 
groups, and the pain reduction was not associated with 
any reduction in psychological distress, improvement in 
overall health related quality of life nor neck function.
4.2   Optimal cryoprobe position?
The short-lasting effect of cryoneurolysis may reflect 
that the endoneurium and basal lamina of the Schwann 
cells may remain intact despite the cryoablation and 
the nerve can regenerate within a few weeks [20–22]. 
However, in our study the insertion of cryoprobes was 
only guided by anatomical (muscular and bony) land-
marks and nerve stimulation. The operator could thus 
not visualize the exact distance to the nerve trunks 
which is critical as the ice-ball, surrounding the probe 
tip, has a sharp temperature gradient from the centre to 
the surface, equivalent to 10 °C/mm [16]. The cryoprobes 
should therefore not be placed more than 4–5 mm away 
from the target nerve.
Previous studies have demonstrated considerable 
interindividual variations in the configuration of the nerve 
trunks [36–38] and distance between GON and the midline 
of the intermastoid line [37, 39]. The probe position might 
thus have been suboptimally placed. The introduction 
of new image-guided techniques is from this perspective 
highly interesting. In a small feasibility study [40] partici-
pants with unilateral occipital neuralgia were subjected 
to nerve stimulation and CT guided cryoneurolysis. Five of 
the six participants reported more than 50% pain reduc-
tion at the 3-month follow-up. This is comparable with our 
findings during the first 8 weeks, but superior to our find-
ings after 12  weeks. CT is, however, a resource intensive 
procedure with high radiation exposure and ultrasound 
guidance is probably a more feasible technique for occipi-
tal neurolysis. Pingree and coworkers performed a small, 
non-controlled study on patients with occipital neural-
gia or CEH to investigate the effect of ultrasound-guided 
GON block [41] at the point where the nerve courses 
superficially to the obliquus capitis inferior muscle. They 
reported significant pain reduction after 4  weeks. In a 
more recent publication Stogicza et al. describes an ultra-
sound guided technique to identify the proximal GON, 
between C2  spinous and C1 transverse process over the 
inferior oblique capitis muscle, for neurolysis of the proxi-
mal GON [42]. In future studies ultrasound guided tech-
niques should thus be applied, but our approach is still 
widely used clinically, and we therefore find our results 
highly relevant.
4.3   Patient selection
The short-lasting effect could also reflect a suboptimal 
selection of participants. In a small retrospective study 
(n: 38) with occipital neuralgia patients subjected to uni-
lateral or bilateral occipital cryoneurolysis, those with a 
moderate response to the test block (50–74% pain relief) 
reported 45% relief after an average of 4 months (which 
is a slightly inferior to our data), while patients with 
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>75% relief to the test block had still 71% pain relief after 
8  months [43]. The paper does not provide information 
about which time point(s) the response was assessed, but 
the findings may indicate that a stricter patient selection 
might have improved the results. In our study the selec-
tion was based on one single test block and usually >50% 
pain reduction, but the success rates did not improve by 
excluding 10 participants who reported <50% pain reduc-
tion to the test block.
4.4   Side effects and complications
One-third of the participants (31%) rated the cryoneuroly-
sis procedure as moderate to very uncomfortable. Minor 
side effects were rather common (29%), restricted to the 
first week, and included symptoms like local tenderness, 
dizziness, and sedation. We observed one potentially 
serious complication after an injection of bupivacaine 
and methylprednisolone. The participant was admitted to 
the intensive care unit and recovered without any seque-
lae. The examination gave no clear explanation. However, 
this case emphasizes the need for complication readiness 
during such procedures. It should also be noted that this 
study, with a small sample size and limited follow up, 
cannot provide evidence regarding the risk of occipital 
cryoneurolysis, particularly not when repeated over time.
4.5   Strengths and other limitations 
of the study
An important strength of the present study is the rand-
omized, controlled and blinded design. Both participants 
and assessor were kept blinded throughout the follow up. 
The study had also a small drop-out rate and low number of 
missing values. Furthermore, the primary outcome measure 
was based on 42 daily pain records during the first 6 weeks 
and weekly pain records the next 11 weeks, which makes it 
a robust measure. With one single and well-trained inter-
ventionist, performing the treatments, we could reduce the 
statistical variance which is essential to demonstrate how 
effective these interventions might be in a clinical setting. 
The 18 week follow-up was also long enough to define the 
effect duration of occipital cryoneurolysis. 
As shown in Table 1 the sample is representative for 
patients suffering from CEH [2, 5]. They reported long 
duration (average 13 years) of intense headache, moder-
ately limited range of neck movement, phychological dis-
tress, and impaired health related quality of life. Although 
a high proportion (42%) suffered from migraine, only a 
few attacks were reported during the follow up. All these 
factors, listed above, increase the validity and generalis-
ability of our findings.
A limitation is that we did not assess how effective the 
blinding procedure was. A “blinding test” has therefore 
been recommended in later years and self-assessment of 
pain intensity may be subjected to bias. With a limited 
sample size of 52 patients the study is also hampered by 
the risk of type II error.
5   Conclusion
For patients with CEH occipital cryoneurolysis and injec-
tions of a corticosteroid combined with a local anaesthetic 
provide substantial pain reduction but with a limited 
duration. We found no significant difference between the 
two treatments. The pain reduction was associated with 
a trend towards reduced opioid consumption, but no or 
minimal improvement in health-related quality of life, 
neck function and psychological distress.
6   Implications
We suggest that occipital cryoneurolysis or steroid injec-
tions is restricted to highly selected patients where 
non-invasive treatment is insufficient and who respond 
substantially to occipital test blocks. The effect can 
probably be improved and extended by including an 
 ultrasound-guided technique. Potential adverse effects 
by repeated occipital cryoneurolysis sessions are not well 
documented and beyond the scope of this study, but scar 
and neuroma formation [44], and risk of neuropathic pain 
[45] have been discussed by other researchers.
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